Liakou Aikaterini I, Tsantes Andreas G, Bompou Evangelia-Konstantina, Kalamata Magdalini, Agiasofitou Efthymia, Vladeni Soultana, Dragoutsou Angeliki, Tsante Konstantina A, Ioannou Petros, Chatzidimitriou Eleni, Kotsafti Ourania, Samonis George, Vrioni Georgia, Bonovas Stefanos, Stratigos Alexander I
1st Department of Dermatology-Venereology, "Andreas Sygros" Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece.
Laboratory of Haematology and Blood Bank Unit, "Attikon" Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
Microorganisms. 2025 Feb 27;13(3):542. doi: 10.3390/microorganisms13030542.
COVID-19 disease has been associated with flares or new onsets of various autoinflammatory diseases such as psoriasis and atopic dermatitis. Our aim is to investigate the occurrence and risk factors of flares or new onsets of Hidradenitis Suppurativa (HS) following COVID-19 disease.
A retrospective cohort study was performed including 310 patients with HS following COVID-19 disease. Data on the rate of HS flares, new lesions, time of flare onset, and flare duration were recorded. Demographics, clinical characteristics, and treatment parameters were compared between patients with and without HS flares.
HS flares developed in 69 (22.2%) patients, with 14 experiencing their first episode. The median period between COVID-19 and flare onset was 17 days, with a median flare duration of 14 days. For new HS onset, the median period was 9.5 days, and the median duration was 13 days. Biologic treatment was less common in patients with flares (7.2% vs. 23.2%, = 0.003), and fewer patients with flares were vaccinated (81.1% vs. 99.1%, < 0.001). Multivariable analysis showed lower risk for flares in those receiving biologics (aOR = 0.14, = 0.002) and those who were vaccinated (aOR = 0.02, < 0.001).
COVID-19 may trigger HS flares and new onset, with biologic treatment and vaccination offering protection.
新型冠状病毒肺炎（COVID-19）疾病与各种自身炎症性疾病（如银屑病和特应性皮炎）的发作或新发有关。我们的目的是调查COVID-19疾病后化脓性汗腺炎（HS）发作或新发的发生率及危险因素。
进行了一项回顾性队列研究，纳入310例COVID-19疾病后的HS患者。记录HS发作率、新发病变、发作开始时间和发作持续时间的数据。比较有和没有HS发作的患者的人口统计学、临床特征和治疗参数。
69例（22.2%）患者出现HS发作，其中14例为首次发作。COVID-19与发作开始之间的中位时间为17天，中位发作持续时间为14天。对于新发生的HS，中位时间为9.5天，中位持续时间为13天。发作患者中生物治疗较少见（7.2%对23.2%，P = 0.003），发作患者中接种疫苗的较少（81.1%对99.1%，P < 0.001）。多变量分析显示，接受生物治疗的患者（调整后比值比[aOR]=0.14，P = 0.002）和接种疫苗的患者（aOR = 0.02，P < 0.001）发作风险较低。
COVID-19可能触发HS发作和新发，生物治疗和接种疫苗具有保护作用。
